Emeka had gone for a routine pre-employment medical. The hepatitis B result — HBsAg positive — was not what he expected. But chronic hepatitis B caught before liver damage begins is very different from hepatitis B discovered when cirrhosis has already developed. The test found it early.
Finance manager, Ikeja. Presented for pre-employment medical at a new firm — required a hepatitis B test as part of the standard panel. No symptoms. No known prior hepatitis B testing. Not vaccinated against hepatitis B.
Hepatitis B ProfileEmeka had done pre-employment medicals before. Blood pressure checked: normal. Full blood count: normal. He was fit, didn't smoke, exercised twice a week. The hepatitis B test was just another box on the form. He had not been vaccinated against hepatitis B — it had not been part of the childhood vaccination schedule when he was growing up in the 1990s.
The Mascot Healthcare doctor called him back for the result personally. "Your hepatitis B surface antigen is positive," she said. "This means you have hepatitis B." Emeka sat quietly for a moment. "Is that serious?" he asked. "It can be," the doctor said. "But we found it before it has caused damage. That matters enormously."
A full hepatitis B profile was completed: HBsAg positive, HBeAg negative, anti-HBe positive, HBV DNA 2,400 IU/mL. ALT (liver enzyme): 34 U/L — normal. This profile was consistent with chronic hepatitis B in the inactive carrier phase — low replication, normal liver function.
A hepatitis B profile is a panel of blood markers that together determine whether a person is currently infected, immune, or susceptible — and if infected, whether the infection is in an active or inactive phase.
Positive = current hepatitis B infection. Negative = not currently infected. Persistence > 6 months = chronic infection.
Positive = immune (from vaccination or past infection resolved). Provides protection.
Marker of active viral replication — high infectivity. Negative HBeAg with low viral load = less active phase.
Suggests immune control of viral replication — lower infectivity phase.
Quantifies actual virus in blood — guides treatment decisions. Emeka's: 2,400 IU/mL (low-level viraemia).
Emeka had likely acquired hepatitis B in early childhood — mother-to-child transmission at birth or through early family contact is the predominant route in Nigeria, where hepatitis B prevalence is approximately 8–10% in the general population. He had never been tested because he had never had symptoms.
Chronic hepatitis B is called "the silent disease" because most people — particularly those in the inactive carrier phase — have no symptoms until significant liver damage has occurred. Cirrhosis and hepatocellular carcinoma (liver cancer) develop silently over decades. Annual monitoring is the only way to detect transition to active disease early.
Emeka's profile confirmed chronic hepatitis B in the inactive carrier phase: HBsAg positive, HBeAg negative (no active replication marker), anti-HBe positive (immune response), HBV DNA 2,400 IU/mL (low-level), ALT normal. Liver ultrasound: normal liver size and echo-texture — no cirrhosis, no focal lesions.
Treatment was not indicated at this stage (ALT normal, HBV DNA below treatment threshold, no significant fibrosis). However, monitoring was essential: HBV DNA, ALT, and liver ultrasound every 6 months; AFP (alpha-fetoprotein for hepatocellular carcinoma screening) every 6 months.
Emeka's family members were counselled to test for hepatitis B status and, if susceptible (HBsAg negative, anti-HBs negative), to receive the hepatitis B vaccination series.
Chronic hepatitis B — inactive carrier phase. HBsAg+, HBeAg−, HBV DNA 2,400 IU/mL, ALT normal, liver normal on scan. No cirrhosis.
6-monthly monitoring: HBV DNA, ALT, liver ultrasound, AFP; gastroenterology referral for specialist oversight; family member testing and vaccination; alcohol abstinence advised; hepatitis A vaccination offered.
At 6 months: HBV DNA 1,800 IU/mL (stable), ALT normal, liver ultrasound normal. At 12 months: HBV DNA 900 IU/mL (further decline), AFP normal. Monitoring continues.
Emeka understands his condition, attends monitoring appointments, and has arranged for his wife and two children to be tested and vaccinated. No evidence of progressive liver disease at 12 months.
Hepatitis B in Nigeria is common and overwhelmingly undiagnosed. Most people who carry the virus have no symptoms — the damage accumulates silently over decades. Testing costs and takes 24 hours. Not testing costs a functioning liver.
Chronic hepatitis B found in the inactive phase — before liver damage — is manageable with monitoring and, when needed, antivirals. The goal is to prevent the progression to cirrhosis and liver cancer that kills tens of thousands of Nigerians annually.
You could have hepatitis B and feel completely healthy for 20 years. A simple blood test tells you your status — and early monitoring prevents the complications that show up silently decades later.
Book online or via WhatsApp — same-day results on most tests, transparent pricing.